← Back to Search

PSMA-targeted PET Imaging for Prostate Cancer (GuideView Trial)

Phase 2 & 3
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 (0, 0-5, 15, 30, 60, 120, 180-240, 300 minutes post infusion)
Awards & highlights

GuideView Trial Summary

This trial will evaluate a PET imaging agent to detect and localize prostate cancer tumors in 195 participants.

Eligible Conditions
  • Prostate Cancer

GuideView Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 (0, 0-5, 15, 30, 60, 120, 180-240, 300 minutes post infusion)
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 (0, 0-5, 15, 30, 60, 120, 180-240, 300 minutes post infusion) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Patient-level sensitivity of [18F]CTT1057
Region-level specificity of [18F]CTT1057
Secondary outcome measures
Area under the [18F]CTT1057 concentration-time curve from time zero to the time of last quantifiable concentration (AUClast)
Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of [18F]CTT1057
Characterize the safety and tolerability of [18F]CTT1057
+18 more

GuideView Trial Design

1Treatment groups
Experimental Treatment
Group I: PET/CT imaging with [18F]CTT1057Experimental Treatment1 Intervention
All eligible participants will be enrolled to receive [18F]CTT1057 imaging agent on Day 1 and have PET/CT scan
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[18F]CTT1057
2021
Completed Phase 3
~370

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,855 Previous Clinical Trials
4,197,165 Total Patients Enrolled
32 Trials studying Prostate Cancer
5,650 Patients Enrolled for Prostate Cancer

Media Library

PET/CT imaging with [18F]CTT1057 Clinical Trial Eligibility Overview. Trial Name: NCT04838626 — Phase 2 & 3
Prostate Cancer Research Study Groups: PET/CT imaging with [18F]CTT1057
Prostate Cancer Clinical Trial 2023: PET/CT imaging with [18F]CTT1057 Highlights & Side Effects. Trial Name: NCT04838626 — Phase 2 & 3
PET/CT imaging with [18F]CTT1057 2023 Treatment Timeline for Medical Study. Trial Name: NCT04838626 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals is the clinical trial currently treating?

"Affirmative. Clinicaltrials.gov's records show that this clinical trial, originally posted on September 7th 2021, is still actively looking for participants. 195 individuals are needed to be recruited from 13 different medical centres."

Answered by AI

Is access to this experiment currently available to participants?

"Affirmative. The clinical trial is actively recruiting and the details provided on clinicaltrials.gov indicate that it was first posted in September of 2021 with a recent update occuring in March of 2023. 195 participants are desired across 13 different sites."

Answered by AI

What other researches have explored the potential of [18F]CTT1057 in combination with PET/CT imaging?

"At present, two medical trials are underway to explore PET/CT imaging with [18F]CTT1057. Of these studies, two have entered their third phase of testing. Although the majority of research is based in Sacramento, California, there are 23 different sites that offer this type of treatment."

Answered by AI

Is this research pioneering in its nature?

"At present, two distinct experiments are assessing the efficacy of PET/CT imaging with [18F] CTT1057 across 6 cities and 5 nations. The trailblazer for this endeavor was sponsored by Novartis Pharmaceuticals in 2021; it involved 195 participants and achieved Phase 2 & 3 of its drug approval process. Subsequently, three additional studies have been performed on this topic."

Answered by AI

How many medical facilities are currently administering this research endeavor?

"This research is presently recruiting participants out of a total of 13 clinics. These medical sites are situated in Barcelona, Toulouse Cedex 4 and Rozzano with an additional 10 spots around the world. It would be advantageous for individuals to select the closest testing centre to minimize time consumption related to travel if they decide to take part."

Answered by AI

What purpose is this experiment attempting to satisfy?

"According to Novartis Pharmaceuticals, the main outcome of this trial will be ascertained through [18F]CTT1057 PET imaging compared with histopathology results taken within 6 weeks. They are also measuring secondary endpoints such as Region-level positive predictive value and characterizing safety profiles by assessing adverse events over a 14 day period. Additionally, they will analyze venous whole blood samples from 10 patients for activity-based pharmacokinetics characterization in order to list and summarize volume distribution during terminal elimination."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
2021. "Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04838626.
~52 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top